financing

The Israeli-based startup will use the funds to continue development of its EpiCheck methylation platform and to develop the Lung EpiCheck assay.

The firm, a University of Edinburgh spinout, will use the funding to in-license its BioCollector liquid biopsy platform and launch initial trials. 

Scipher will use the proceeds to further commercialize PrismRA, a molecular test intended to guide treatment decisions for patients with rheumatoid arthritis.

The firm's CEO said that its MDx system is available for research use and going through CE-IVD marking ahead of its full commercial launch.

CellMax also completed a Series C financing round to speed up development of itsFirstSight liquid biopsy test to detect colorectal cancer and precancer polyps.

The startup will use the funds to support R&D and to launch its Qsant urine test to help determine if a patient's body is rejecting a kidney transplant.

Boston-based Variantyx will expand its whole-genome sequencing testing method to oncology from rare inherited and neurological disorders.

The firm plans to use $561 million of the net proceeds to fund the majority of its planned $591 million acquisition of Oxford Immunotec.

The Chinese company said it would use some of the funding to advance its integrated diagnostics research and development pipeline.